股票交易异常波动公告 证券代码：002172 证券简称：澳洋健康 公告编号：2025-22 江苏澳洋健康产业股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚 假记载、误导性陈述或者重大遗漏负连带责任。 5、经查询，公司控股股东澳洋集团、实际控制人沈学如先生在股票异常波 动期间未买卖公司股票。 三、是否存在应披露未披露的重大信息的声明 一、股票交易异常波动情况 江苏澳洋健康产业股份有限公司（以下简称"公司"）股票价格于 2025 年 6 月 9 日、10 日连续两个交易日收盘价格涨幅偏离值累计超过 20%，根据《深圳 证券交易所交易规则》的有关规定，属于股票交易异常波动情形。 二、公司关注并核实的相关情况 针对公司股票交易异常波动，公司对有关事项进行了核查，并通过问询公司 控股股东及实际控制人，有关情况说明如下： 1、经核查，公司前期披露的信息不存在需要更正、补充之处； 2、经核查，公司未发现近期公共媒体报道了可能或已经对本公司股票交易 价格产生较大影响的未公开重大信息； 3、经核查，公司目前经营情况正常，内外部经营环境未发生重大变化； 4、经核查，公司、公司 ...

Core Viewpoint - The company, Aoyang Health, announced that there are no undisclosed significant matters that should have been disclosed, following a significant stock price fluctuation over two consecutive trading days [1] Group 1: Stock Performance - Aoyang Health's stock price experienced an abnormal fluctuation, with a cumulative price increase exceeding 20% over the trading days of June 9 and June 10, 2025 [1] - The company confirmed that the information previously disclosed does not require correction or supplementation [1] Group 2: Company Operations - The company stated that its current operational situation is normal, and there have been no significant changes in the internal or external operating environment [1] - Aoyang Group, the controlling shareholder, and the actual controller, Mr. Shen Xueru, have not engaged in any buying or selling of the company's stock during the period of abnormal price fluctuation [1]

Market Overview - The A-share market showed mixed performance on June 10, with the Shanghai Composite Index experiencing a decline of 0.44% to close at 3384.82 points, while the ChiNext Index fell by 1.17% to 2037.27 points [5][9] - The total trading volume in the Shanghai and Shenzhen markets reached 14,153 billion yuan, an increase of 1,289 billion yuan compared to the previous trading day [5] Sector Performance - Bank stocks performed strongly against the market trend, with several banks, including Nanjing Bank and Industrial Bank, reaching historical highs [7] - The pharmaceutical and biotechnology sectors continued to show strength, with multiple stocks hitting the daily limit or rising over 10% [7] - The TMT sector faced a broad adjustment, with significant declines in semiconductor, AI applications, and fintech stocks [3][8] Stock Movements - A total of 79 stocks saw an increase of over 9%, while 10 stocks experienced a decline of over 9% [6] - Notable declines were observed in the computer sector, with some stocks dropping over 30% [7][8] Market Sentiment and Outlook - Analysts predict a steady upward trend in the short term, supported by a loose monetary policy and potential fiscal measures [9][10] - The market is expected to remain in a wide-ranging fluctuation phase, with a focus on policy developments and external market conditions [10][11] - The investment focus is suggested to be on sectors that are decoupled from the macroeconomic cycle and have structural growth potential [10][12]

Industry Overview - The hair medical sector has shown significant activity recently, with the sector index reaching a new high as of June 10, 2023, driven by active stock performances from companies like Aoyang Health and Kanghui Medical [1] - The hair medical services can be divided into hair transplant services and medical hair care services, with hair transplant services currently dominating the market [1] - The growing trend of beauty economy and self-consumption is leading consumers to invest more time and money in hair health and aesthetics, which is expected to drive continuous growth in the hair medical industry [1] - According to Frost & Sullivan, the market size of hair medical services in China is projected to reach 138.1 billion yuan by 2030, with a CAGR of 22.3% from 2020 to 2030 [1] Market Dynamics - The medical hair care market is expected to grow rapidly due to the high frequency and repurchase characteristics of hair care services, with the "hair transplant and care" integration trend driving this growth [2] - By 2030, the medical hair care services are anticipated to account for 45.3% of the total hair medical services market in China, becoming a significant driver of industry development [2] Key Companies - Zhendong Pharmaceutical (300158): The company's main product, Dafeixin Minoxidil Solution, is the only topical medication approved by both the FDA and NMPA for treating hair loss [2] - Huilong Co., Ltd. (002556): The company offers hair growth and hair loss treatment products, including Zhi Zhi Hair Growth Tablets and Compound Ginseng Phenol Solution, which have national drug approval [2] - Kanghui Pharmaceutical (603139): The company has several drugs listed in the national medical insurance directory, including hair loss treatment tablets [3] - Aoyang Health: The company's subsidiary, Weien Medical Beauty, includes hair transplant services [4] - Tainkang (301263): The company is applying for a one-time import of raw materials for Baricitinib, which is under research for hair growth indications [4] - Kangyuan Pharmaceutical: The new hair loss treatment drug Minoxidil Tincture has completed registration verification and GMP compliance checks [4] - Langzi Co., Ltd. (002612): The company has medical beauty institutions that offer hair transplant-related services [5] - Huabang Health (002004): The company has a hair transplant center under Maan Skin, utilizing MN-FUE hair transplant technology for patient treatment [6]

Core Viewpoint - The article discusses the Chinese government's efforts to enhance and improve people's livelihoods through various policies and initiatives aimed at addressing social welfare, particularly focusing on the elderly and children. Group 1: Policy Initiatives - The Ministry of Finance is accelerating the establishment of a childcare subsidy system to better meet the service needs of the elderly and children [2] - The National Development and Reform Commission (NDRC) expects a 30% increase in the central budget investment for social undertakings compared to the end of the 13th Five-Year Plan [3] - The NDRC emphasizes the importance of coordinating and integrating policies to prevent fragmentation and ensure effective implementation [4] Group 2: Targeted Measures - The NDRC's recent opinion highlights the need for targeted policies to address key issues such as education, healthcare, and social services for the elderly and children, aiming to enhance the sense of gain among the public [5] - Specific measures include actions to increase income for low-income rural populations through skill enhancement and employment opportunities [5] - The Ministry of Civil Affairs is working on improving the social assistance system to ensure fair and sustainable support for low-income groups [6] Group 3: Employment and Insurance Policies - The Ministry of Human Resources and Social Security is developing insurance policies tailored to new employment forms and income characteristics, focusing on flexible workers and migrant workers [7] - The ministry plans to eliminate household registration restrictions for flexible employment insurance and promote participation in pension insurance [7]

Group 1 - The A-share market saw significant movements in the three-child policy concept sector, with Hanyu Pharmaceutical rising over 16.5% [1] - Aoyang Health reached a trading limit, while Kanghui Pharmaceutical and Zhujiang Piano also hit the trading limit [1] - Jeya Co., Zhujiang Co., and Taihu Snow all experienced increases of over 7% [1]

Group 1 - The core viewpoint of the article highlights the significant rise in infant and child-related stocks, particularly noting the surge in shares of Aoyang Health, Kanghui Pharmaceutical, and Zhujiang Piano, which reached their daily limit [1] - The Ministry of Finance's Social Security Department, represented by Ge Zhihua, announced efforts to enhance the elderly and child care service system, indicating a focus on improving the quality of inclusive childcare services [1] - The establishment of a childcare subsidy system is being prioritized to support the development of these services, which is expected to positively impact related companies in the sector [1] Group 2 - Aoyang Health, Kanghui Pharmaceutical, and Zhujiang Piano experienced a limit-up in their stock prices, while other companies like Zhujiang Co., Jieya Co., Beiyinmei, and Haoyue Nursing saw increases of over 5% [1] - Other companies in the sector, such as Kexin Co., Knight Dairy, and Aiyingshi, also showed positive stock performance, indicating a broader market trend in the infant and child care industry [1]

Group 1: Market Activity - 13 stocks had a closing order amount exceeding 100 million yuan, with the top four being Yiming Pharmaceutical (4.88 billion yuan), Zhongsheng Pharmaceutical (3.28 billion yuan), Jinying Co. (2.98 billion yuan), and Jianghuai Automobile (2.18 billion yuan) [3] - Yiming Pharmaceutical ranked first in closing order volume with 273,900 hands, followed by Zhongsheng Pharmaceutical and Yuheng Pharmaceutical, both exceeding 200,000 hands [2] Group 2: Company Announcements - Yiming Pharmaceutical announced that its actual controller, Gao Fan, signed a share transfer agreement to transfer 23% of the company's shares to Beijing Fuhai at a price of 15.1 yuan per share, totaling 662 million yuan [3] - The company reported revenues of 857 million yuan, 667 million yuan, and 652 million yuan for 2022, 2023, and 2024 respectively, with net profits of 44 million yuan, 15 million yuan, and 46 million yuan [3] Group 3: Sector Performance - The innovative drug sector saw several stocks hit the daily limit, including Changshan Pharmaceutical, Haichen Pharmaceutical, Shutaishen, and Ruizhizhi Pharmaceutical [4] - Haichen Pharmaceutical's main products include self-developed drugs that are selected in national drug procurement [4] Group 4: Investment Trends - The stocks with the highest net purchases on the Dragon and Tiger list included Changshan Pharmaceutical, Haichen Pharmaceutical, and Hahan Huatu, with net purchases exceeding 100 million yuan [8] - Institutions showed significant net buying in stocks like Kuaibao and Rejing Biological, while net selling was observed in Yuyin Co., Hengbao Co., and Xiongdi Technology [8]

Group 1 - The hair medical concept sector increased by 3.82%, ranking fifth among concept sectors, with 18 stocks rising, including Aoyang Health which hit the daily limit, and Tainkang, Jiuzhitang, and Kangyuan Pharmaceutical showing significant gains of 13.80%, 5.79%, and 5.73% respectively [1][2] - The hair medical concept sector attracted a net inflow of 132 million yuan from main funds today, with 10 stocks receiving net inflows, and 7 stocks seeing inflows exceeding 10 million yuan, led by Aoyang Health with a net inflow of 94.61 million yuan [2][3] - Aoyang Health, Nengte Technology, and Shuiyang Shares had the highest net inflow ratios, with 42.28%, 6.86%, and 6.82% respectively [3][4] Group 2 - The top stocks in the hair medical concept sector based on net inflow include Aoyang Health, Shuiyang Shares, and Langzi Shares, with respective net inflows of 94.61 million yuan, 53.93 million yuan, and 24.89 million yuan [2][3] - The trading performance of Aoyang Health showed a daily increase of 10.08% with a turnover rate of 7.13%, while other notable performers included Shuiyang Shares and Langzi Shares with increases of 4.22% and 3.10% respectively [3][4] - The overall market sentiment in the hair medical sector appears positive, as indicated by the significant inflows and stock performance [1][2]

Company Overview - Aoyang Health's closing price on May 28 was 3.57 yuan, down 1.38%, with a rolling PE ratio of 96.52 times and a total market value of 2.734 billion yuan [1] - The company operates in the medical services, pharmaceutical distribution, and biotechnology sectors, with main products including medical services and pharmaceutical logistics [1] Financial Performance - In Q1 2025, Aoyang Health reported revenue of 452 million yuan, a year-on-year decrease of 22.27%, and a net profit of 18.4992 million yuan, down 39.82% [2] - The company's gross profit margin was 15.09% [2] Shareholder Information - As of March 31, 2025, Aoyang Health had 53,714 shareholders, a decrease of 3,624 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Comparison - The average PE ratio for the medical services industry is 38.04 times, with a median of 42.05 times, placing Aoyang Health at 41st in the industry ranking [2] - The company’s PE ratio is significantly higher than the industry average, indicating potential overvaluation compared to peers [2] Achievements and Recognition - Aoyang Health's medical institutions have received various honors, including awards in national hospital quality improvement competitions and recognition as a top non-public hospital in China [1] - The company has signed an agreement with the China Trauma Rescue Alliance to enhance its trauma care capabilities [1]